The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1250 articles
Kelly Osbourne has responded to critics who have been commenting on her weight loss. She shared that she has been struggling to eat since the death of her father. Sharon Osbourne defended her daughter, emphasizing the emotional toll of losing her father.
Mounjaro, a drug by Eli Lilly, is set to be added to China's state health insurance on January 1st. This inclusion could intensify competition among pharmaceutical companies. The move aims to improve access for China's large population.
Urban elites are currently the main drivers behind the increasing popularity of GLP-1 weight loss medications. Changes in distribution strategies and price adjustments could potentially transform this trend. These factors could democratize access to these treatments.
As the holiday season approaches, many individuals express concerns regarding potential weight gain. Prestige Men's Health in Holladay is offering medically supervised weight-loss programs using GLP-1 treatments like semaglutide, providing screening, labs, and continuous monitoring. This comes as more Utah residents seek medical guidance for weight management during this time.
Cipla has released Yurpeak (tirzepatide), a weekly injectable medication designed for adults managing obesity and type 2 diabetes. As the second tirzepatide brand from Lilly available in India, Yurpeak will be accessible through prescription in a user-friendly KwikPen.
A clinical trial is underway to test a new weight-loss treatment for cats using a drug class similar to Ozempic. The study, called MEOW-1, involves an implant administering medication to help overweight cats shed pounds.
An ITV presenter, known for her financial expertise on Lorraine, has publicly discussed her weight loss journey. She attributes her four-stone weight loss to the use of Mounjaro, resulting in a significant change in her dress size.
The rise of GLP-1 drugs has sparked interest across various industries, including beauty. While some claims may seem like clickbait, the need for skincare innovation to address skin changes related to these medications is real. Experts and research suggest GLP-1 skincare is a legitimate response to these changes.
An affordable and readily accessible medication is gaining attention as a potential solution for curbing alcohol cravings, drawing comparisons to the way GLP-1 drugs manage food cravings. Naltrexone, by impacting dopamine-reward pathways, reduces the satisfying feeling associated with alcohol consumption, thus diminishing the desire for it. Research and anecdotal evidence suggest it could be a game-changer for many.
